Best options for treating relapsed/refractory PTCLMarch 8, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
High efficacy, no safety signals for herpes zoster vaccine post-HSCTMarch 7, 2018Lymphoma & Plasma Cell Disorders
Export protein inhibitor shows activity against refractory myelomaMarch 1, 2018Lymphoma & Plasma Cell Disorders
High objective response rate, OS seen with ATA129 in PTLDFebruary 24, 2018Lymphoma & Plasma Cell Disorders
Baseline stress signals need for psychological help in CLLFebruary 23, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Basiliximab/BEAM may improve post-ASCT outcomes in PTCLFebruary 21, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
NF-kappaB pathway could help solve resistance problem in mantle cell lymphomaFebruary 16, 2018Lymphoma & Plasma Cell Disorders
Denosumab on par with zoledronic acid for multiple myeloma bone diseaseFebruary 16, 2018Lymphoma & Plasma Cell Disorders
FIRST trial analysis shows more benefit for lenalidomideFebruary 12, 2018Lymphoma & Plasma Cell Disorders
Three-drug combo delivers PFS for myeloma in OPTIMISMM trialFebruary 6, 2018Lymphoma & Plasma Cell Disorders
TRANSCEND NHL trial identifies window for CAR T expansionFebruary 6, 2018Lymphoma & Plasma Cell DisordersFollicular Lymphoma
CLL Index proves accurate in predicting survival, time to treatFebruary 5, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
